Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hypertension
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hypertension
    TopAbstracts in Hypertension 07/01/2009 - (DGNews)
    Certain Biomarkers Have Limitations in Predicting Cardiovascular Events - (DGNews)
    Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study - (BMJ)
    TopAbstracts in Hypertension 06/24/2009 - (DGNews)
    TopAbstracts in Hypertension 06/17/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Hypertension
    Thrombotic Thrombocytopenic Purpura: The Masquerader
    Innovative Strategies in Cardiometabolic Risk Reduction
    Diuretics for the Treatment of Hypertension
    Managing Hypertension: Addressing the Challenges in Special Populations

    Webcasts/CME archive

     Recent cases - Hypertension
      Medical Management of a Pregnancy Woman with Moderate Renal Insufficiency and Superimposed Preclampsia
      Malignant Hypertension and Acute Aortic Dissection Associated with Caffeine-Based Ephedra-Free Dietary Supplements: A Case Report
      Giant Right Coronary Artery Aneurysm: Case Report and Literature Review
      Normalization of Systemic Arterial Hypertension Following Removal of Posterior Fossa Hemangioblastoma: A Case Report
      Headache and Seizure on Postpartum Day 5: Late Postpartum Eclampsia

      Cases archive
        




      my personal edition > hypertension > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Controlled Onset Extended Release Verapamil At Bedtime May Better Control Morning Blood Pressure, Heart Rate

      A DGReview of :"Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising."
      American Heart Journal

      10/09/2002
      By Andrew A. Skolnick


      The administration of controlled onset extended release verapamil at bedtime may control morning blood pressure, heart rate and heart rate systolic blood pressure better than conventional, antihypertensive agents taken in the morning.

      Therapeutic agents for the treatment of hypertension may differ in their efficacy during the early-morning period, when the risk of cardiovascular events is highest.

      William B. White, MD, and colleagues at the University of Connecticut School of Medicine, in Farmington, Connecticut, United States, compared the haemodynamic effects of a chronotherapeutic delivery system of verapamil taken at bedtime, versus the conventional morning administration of enalapril or losartan.

      The study involved 357 men and women with an untreated sitting diastolic blood pressure of 95 to 114 mm Hg and ambulatory daytime diastolic blood pressure greater than or equal to 85 mm Hg.

      The patients were randomized to receive either COER-verapamil hydrochloride each evening (240 mg titrated to 360 mg), enalapril each morning (10 mg titrated to 20 mg), losartan each morning (50 mg titrated to 100 mg), or placebo. Early morning assessments of blood pressure, heart rate, and the heart rate systolic blood pressure product were performed by use of 24-hour ambulatory recordings after four weeks of low dose and eight weeks of high dose therapy.

      Results were similar at weeks four and eight for all treatment groups, except that the magnitude of change was greater at week eight. After eight weeks of treatment, reductions in early morning blood pressure by COER-verapamil were significantly greater (-15/-10 mm Hg) than enalapril (-9/-7 mm Hg) and losartan (-8/-5 mm Hg), the researchers reported.

      COER-verapamil also led to greater reductions in morning heart rate, the rate-pressure product, and the rate-of-rise of blood pressure compared with the other two active treatment groups. Reductions in mean 24-hour blood pressure were greater in patients treated with COER-verapamil compared with those taking placebo or losartan, and was similar to reductions in patients treated with enalapril.

      "Bedtime administration of an agent designed to parallel the circadian rhythm of blood pressure and heart rate led to significantly greater early morning haemodynamic effects compared with other conventional once-daily antihypertensive agents dosed in the morning," the researchers concluded.
      Am Heart J 2002; 144: 657-665. "Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising."

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send